New COVID drugs face delays as trials grow more difficult
Saima May Sidik
Nature, 2022, vol. 606, issue 7915, 637-637
Abstract:
Fewer people are eligible for the massive studies needed to test treatments for severe COVID-19.
Keywords: SARS-CoV-2; Drug discovery; Medical research; Infection (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:
Downloads: (external link)
https://www.nature.com/articles/d41586-022-01602-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:606:y:2022:i:7915:d:10.1038_d41586-022-01602-5
Ordering information: This journal article can be ordered from
https://www.nature.com/
DOI: 10.1038/d41586-022-01602-5
Access Statistics for this article
Nature is currently edited by Magdalena Skipper
More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().